Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.39 -2.1%	$1.90	$1.30 ▼ $13.07	$52.23M	-0.07	907,892 shs	767,390 shs
CMMB Chemomab Therapeutics	$1.37 -2.1%	$1.21	$0.78 ▼ $2.55	$19.67M	0.55	211,763 shs	143,547 shs
MCRB Seres Therapeutics	$7.05 -2.5%	$10.00	$6.53 ▼ $30.60	$61.56M	2.89	146,297 shs	67,071 shs
PYXS Pyxis Oncology	$1.20 -3.2%	$1.07	$0.83 ▼ $5.39	$74.34M	1.15	739,372 shs	323,951 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	-4.05%	-9.55%	-35.16%	-50.00%	-87.09%
CMMB Chemomab Therapeutics	+2.56%	+0.72%	+6.87%	-14.11%	+60.92%
MCRB Seres Therapeutics	-5.74%	-12.26%	-28.27%	-51.81%	-60.56%
PYXS Pyxis Oncology	+0.81%	+2.48%	+16.98%	+9.73%	-67.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	2.3302 of 5 stars	3.5	0.0	0.0	1.9	3.3	1.3
CMMB Chemomab Therapeutics	3.0047 of 5 stars	3.5	5.0	0.0	1.1	1.7	1.3
MCRB Seres Therapeutics	3.3515 of 5 stars	2.9	3.0	4.6	2.2	0.8	0.0
PYXS Pyxis Oncology	1.541 of 5 stars	3.4	0.0	0.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.08	Buy	$22.60	1,525.90% Upside
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	520.44% Upside
MCRB Seres Therapeutics	1.80	Reduce	$73.67	944.92% Upside
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	650.00% Upside

Current Analyst Ratings Breakdown

Latest CMMB, PYXS, MCRB, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/16/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$11.00 ➝ $10.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/2/2025	BMEA Biomea Fusion	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $3.00
3/31/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/24/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$10.00
3/24/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/20/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$4.74 per share	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$1.54 per share	N/A
MCRB Seres Therapeutics	$126.33M	0.49	N/A	N/A	($0.35) per share	-20.14
PYXS Pyxis Oncology	$16.15M	4.60	N/A	N/A	$2.81 per share	0.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$117.25M	-$3.55	N/A	N/A	N/A	N/A	-118.90%	-93.66%	7/30/2025 (Estimated)
CMMB Chemomab Therapeutics	-$24.22M	-$0.76	N/A	N/A	N/A	N/A	-101.70%	-76.18%	N/A
MCRB Seres Therapeutics	-$113.72M	-$4.60	N/A	N/A	N/A	N/A	N/A	-55.08%	8/12/2025 (Estimated)
PYXS Pyxis Oncology	-$73.79M	-$1.59	N/A	N/A	N/A	N/A	-36.22%	-28.76%	8/13/2025 (Estimated)

Latest CMMB, PYXS, MCRB, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.14	+$0.06	-$0.14	N/A	N/A
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A
3/18/2025	Q4 2024	PYXS Pyxis Oncology	-$0.33	-$0.32	+$0.01	-$0.60	N/A	$16.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.39	3.39
CMMB Chemomab Therapeutics	N/A	4.57	4.57
MCRB Seres Therapeutics	N/A	1.12	1.12
PYXS Pyxis Oncology	N/A	7.33	7.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
CMMB Chemomab Therapeutics	46.05%
MCRB Seres Therapeutics	59.34%
PYXS Pyxis Oncology	39.09%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	27.57%
CMMB Chemomab Therapeutics	11.91%
MCRB Seres Therapeutics	4.70%
PYXS Pyxis Oncology	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	37.57 million	26.25 million	Optionable
CMMB Chemomab Therapeutics	20	14.36 million	12.65 million	Not Optionable
MCRB Seres Therapeutics	330	8.73 million	162.03 million	Optionable
PYXS Pyxis Oncology	60	61.95 million	53.64 million	Optionable

CMMB, PYXS, MCRB, and BMEA Headlines

Recent News About These Companies

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

May 27 at 3:49 AM | americanbankingnews.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Analysts

May 24, 2025 | marketbeat.com

Pyxis Oncology Q2 EPS Forecast Decreased by HC Wainwright

May 23, 2025 | marketbeat.com

HC Wainwright Weighs in on Pyxis Oncology Q1 Earnings

May 22, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)

May 22, 2025 | theglobeandmail.com

Q2 EPS Estimates for Pyxis Oncology Cut by HC Wainwright

May 22, 2025 | americanbankingnews.com

Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from HC Wainwright

May 21, 2025 | marketbeat.com

Leerink Partnrs Forecasts Pyxis Oncology FY2029 Earnings

May 21, 2025 | marketbeat.com

HC Wainwright Comments on Pyxis Oncology Q1 Earnings

May 21, 2025 | americanbankingnews.com

Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright

May 20, 2025 | americanbankingnews.com

Jacobs Levy Equity Management Inc. Raises Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

May 19, 2025 | marketbeat.com

Ridgeback Capital Investments L.P. Takes $560,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS)

May 17, 2025 | marketbeat.com

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | globenewswire.com

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Pyxis Oncology (PYXS) to Release Earnings on Tuesday

May 8, 2025 | marketbeat.com

New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

May 8, 2025 | baystreet.ca

Boothbay Fund Management LLC Sells 201,674 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

May 5, 2025 | marketbeat.com

Pyxis Oncology reveals promising preclinical data for cancer drug

April 27, 2025 | investing.com

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

April 25, 2025 | globenewswire.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

April 23, 2025 | zacks.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

April 16, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, PYXS, MCRB, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.39 -0.03 (-2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 0.00 (-0.36%)

As of 06:31 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Chemomab Therapeutics NASDAQ:CMMB

$1.37 -0.03 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$1.39 +0.02 (+1.75%)

As of 04:52 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Seres Therapeutics NASDAQ:MCRB

$7.05 -0.18 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$7.07 +0.02 (+0.27%)

As of 05:54 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Pyxis Oncology NASDAQ:PYXS

$1.20 -0.04 (-3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$1.25 +0.05 (+3.75%)

As of 05:45 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time